




Licensing Opportunity

Beta2-adrenergic receptor mAb

Scientists at the Georg-August-University generated monoclonal antibodies which specifically react with beta2-adrenergic receptor (**b2AR**) on human leukocytes and other cells with physiological expression levels of this receptor. b2AR is a prototypic **G protein** coupled receptor which is activated by **catecholamines**. It fulfills important roles in the regulation of several organ systems and coordinates functions of the endocrine, neurological and immune system. b2AR mediate glycogenolysis/gluconeogenesis in liver and relaxation of smooth muscle and are important **drug targets** for a wide variety of **cardiovascular, respiratory** and other **diseases**. These antibodies can be used for Immunoblotting, Immunoprecipitation, Immunofluorescence and flow cytometry for monitoring response to pharmaceutical treatment of endocrine, neurological and immune disorders.

Clone: I3D6 and R11E1
 Isotype: IgG1/k
 Concentration: 1.2 mg/ml and 1.1 mg/ml
 Immunogen: human β 2-adrenergic receptor (purified intact receptor)
 Donor strain: Balb/c mouse
 Donor sex: unknown
 Fusion cell line: X63Ag8.653 myeloma cells
 Subcloning: limiting dilution technique, 3x
 Reactivity: Immunoblotting, Immunoprecipitation, Immunofluorescence, Flow cytometry
 Cross-species: no crossreactivity toward rat or murine β 2AR
 Literature: manuscript in preparation



A, Immunoprecipitation and immunoblotting of the β 2AR from β 2AR-expressing HEK cells. HA-tagged receptors were immunoprecipitated with the indicated antibodies and detected with anti-HA mAb. **B**, Immunofluorescence of β 2AR-HEK cells, detection with FITC-labeled R11E1. **C**, Flow cytometry, peripheral blood leukocytes were stained in parallel with anti- β 2AR I3D6-PE and CD56-FITC. >95% of CD56+ NK cells (red circle) in peripheral blood express β 2AR.

We are looking for companies, who are interested in **licensing** these antibodies for selling them to industrial and scientific institutions or for developing advanced **diagnostic tests** and **therapeutic solutions**.